ALK-Abelló (ALK) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Mar, 2026Opening remarks and agenda
The meeting was opened with a welcome to shareholders, both in-person and online, and formalities were confirmed, including legal convening and voting rights representation at 87% of votes and 77% of share capital.
The agenda included reports on company activities, approval of the annual report, allocation of profits, remuneration, board elections, auditor appointment, and an update to the remuneration policy.
Financial performance review
Revenue reached DKK 6.3 billion in 2025, a 15% increase in local currencies, surpassing expectations and marking the seventh consecutive year of growth.
EBIT rose by 53% to DKK 1.7 billion, with the EBIT margin reaching 26%, achieving the long-term target of 25%.
Net profit exceeded DKK 1 billion for the first time, and free cash flow was DKK 1.4 billion, up from negative in 2024.
Gross profit increased to DKK 4.2 billion, with a gross margin of 67%.
All regions saw double-digit growth, with Europe as the largest market, and significant contributions from North America and international markets.
Dividend announcements
The board proposed resuming dividends, with DKK 355 million to be paid for 2025, or DKK 1.6 per share, representing about 30% of net profit.
Latest events from ALK-Abelló
- Q1 saw 12% revenue growth, 50% EBIT surge, and strong pediatric and neffy® product momentum.ALK
Q1 20259 Jul 2026 - Q3 revenue up 18% and EBIT margin at 23%, driven by tablet and JextⓇ sales, with neffyⓇ deal fueling growth.ALK
Q3 20248 Jul 2026 - Aims to double patient reach by 2030, sustain 10%+ growth, and achieve a 25% EBIT margin.ALK
CMD 20248 Jul 2026 - Growth is fueled by pediatric allergy tablets, strong European sales, and innovative launches like Nefy.ALK
Jefferies Global Healthcare Conference 20258 Jul 2026 - Q1 2026 saw record tablet sales, margin expansion, and an upgraded full-year outlook.ALK
Q1 20264 May 2026 - 18% revenue and 22% EBIT growth, upgraded outlook, and strong tablet sales momentum.ALK
Q1 20264 May 2026 - Revenue up 15% and EBIT margin at 26%, led by tablet and anaphylaxis product growth.ALK
Q4 202520 Feb 2026 - Revenue up 15% and EBIT margin at 26%, driven by tablets and anaphylaxis growth.ALK
Q4 202520 Feb 2026 - Q2 revenue up 21% and EBIT margin at 19%, driving upgraded 2024 outlook and strong tablet sales.ALK
Q2 202423 Jan 2026